The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43.
about
ZP1609/Danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design.Lack of Contribution of p66shc and Its Mitochondrial Translocation to Ischemia-Reperfusion Injury and Cardioprotection by Ischemic Preconditioning.Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.
P2860
The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@en
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@nl
type
label
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@en
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@nl
prefLabel
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@en
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@nl
P2093
P2860
P356
P1476
The gap junction modifier ZP16 ...... rom mitochondrial connexin 43.
@en
P2093
Kerstin Boengler
Klaus-Dieter Schlüter
Marko Bulic
Rolf Schreckenberg
P2860
P304
P356
10.1111/BPH.13804
P407
P577
2017-03-30T00:00:00Z